Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

PD-L1 expression in triple-negative breast cancer.

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G.

Cancer Immunol Res. 2014 Apr;2(4):361-70. doi: 10.1158/2326-6066.CIR-13-0127. Epub 2014 Jan 10.

2.

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.

Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32. doi: 10.1038/pcan.2015.39. Epub 2015 Aug 11.

3.

PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.

Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, Wu X, Wang L, Wang J, Liu H.

PLoS One. 2013 Jun 13;8(6):e65821. doi: 10.1371/journal.pone.0065821. Print 2013.

4.

Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.

Park YH, Jung HH, Ahn JS, Im YH.

Biochem Biophys Res Commun. 2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21.

PMID:
23973711
5.

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.

Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, Zhang L, Zhang S, Yang Y.

Cancer Sci. 2016 Nov;107(11):1563-1571. doi: 10.1111/cas.13072.

6.

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.

Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H.

Mol Cancer. 2015 Aug 7;14:149. doi: 10.1186/s12943-015-0421-2.

7.

INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.

Reed DE, Shokat KM.

Mol Cancer Res. 2017 Jun;15(6):765-775. doi: 10.1158/1541-7786.MCR-16-0183. Epub 2017 Feb 14.

8.

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.

Clin Cancer Res. 2015 Sep 1;21(17):4014-21. doi: 10.1158/1078-0432.CCR-15-0016. Epub 2015 May 27.

9.

Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.

Okabe M, Toh U, Iwakuma N, Saku S, Akashi M, Kimitsuki Y, Seki N, Kawahara A, Ogo E, Itoh K, Akagi Y.

Cancer Sci. 2017 Jan;108(1):81-90. doi: 10.1111/cas.13114. Epub 2017 Jan 21.

10.

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS.

Clin Cancer Res. 2013 Feb 1;19(3):598-609. doi: 10.1158/1078-0432.CCR-12-2731. Epub 2012 Oct 24.

11.

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.

Botti G, Collina F, Scognamiglio G, Rao F, Peluso V, De Cecio R, Piezzo M, Landi G, De Laurentiis M, Cantile M, Di Bonito M.

Int J Mol Sci. 2017 Feb 21;18(2). pii: E459. doi: 10.3390/ijms18020459.

12.

Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.

Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, Zhang P.

Immunobiology. 2012 Apr;217(4):385-93. doi: 10.1016/j.imbio.2011.10.016. Epub 2011 Nov 3.

PMID:
22204817
13.

Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S.

J Biol Chem. 2015 Mar 27;290(13):8110-20. doi: 10.1074/jbc.M114.612689. Epub 2015 Feb 2.

14.

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA.

Oncotarget. 2015 Sep 22;6(28):26483-93. doi: 10.18632/oncotarget.4494.

15.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29.

16.

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A.

Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8.

17.

ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.

Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X.

Breast Cancer Res Treat. 2015 Jul;152(2):255-69. doi: 10.1007/s10549-015-3467-3. Epub 2015 Jun 13.

PMID:
26070269
18.

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.

Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B.

PLoS One. 2013 Oct 15;8(10):e77425. doi: 10.1371/journal.pone.0077425. eCollection 2013.

19.

Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.

Cheng G, Fan X, Hao M, Wang J, Zhou X, Sun X.

Mol Cancer. 2016 Apr 30;15(1):30. doi: 10.1186/s12943-016-0515-5.

20.

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.

Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H.

Cancer Sci. 2014 Jul;105(7):779-87. doi: 10.1111/cas.12427. Epub 2014 Jun 2.

Supplemental Content

Support Center